Department of Surgery, Niigata Cancer Center Hospital, Chuo-ku, Niigata 951-8566, Japan.
Anticancer Res. 2009 Nov;29(11):4689-96.
Feasibility and efficacy of S-1 and cisplatin followed by surgery was evaluated, and factors contributing to survival benefit were analyzed.
In total, 120 consecutive patients with highly advanced gastric cancer were treated with S-1 (80 mg/m(2) for 21 consecutive days) and cisplatin (50 mg/m(2) on day 8).
The response rate was 62.5% overall, and 75.7% for these with metastatic lymph nodes. Grade 3/4 adverse events were less than 10%. The median survival time was 41.9 months among 93 patients whose primary lesion was resected. Liver metastasis, R2 resection, poor performance status and lack of response were identified as independent risk factors by a multivariate analysis.
Preoperative chemotherapy with S-1 and cisplatin was effective. The results show the need for different approaches in the treatment of patients with metastases and these without.
评估 S-1 和顺铂序贯手术治疗晚期胃癌的可行性和疗效，并分析影响生存获益的因素。
共对 120 例局部晚期胃癌患者进行 S-1（80 mg/m2，连续 21 天）和顺铂（80 mg/m2，第 8 天）治疗。
总体缓解率为 62.5%，有转移淋巴结的患者缓解率为 75.7%。3/4 级不良事件发生率低于 10%。93 例原发灶切除患者的中位生存时间为 41.9 个月。多因素分析显示肝转移、R2 切除、体力状态差和无反应是独立的危险因素。
S-1 和顺铂术前化疗是有效的。结果表明，对于有转移和无转移的患者，需要采取不同的治疗方法。
